TrialRMD open2021

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials.

Kristen Sweet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.